Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 348 entries
View as:

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Phase: N/A Priority: Normal
NCT ID: NCT06572228 Org: User:
Start: 08/26/24 End: 12/31/26 Due: 12/31/27

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Phase: N/A Priority: Normal
NCT ID: NCT05106387 Org: User:
Start: 10/19/23 End: 12/24/27 Due: 12/24/28

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT01266876 Org: User:
Start: 01/31/11 End: 11/30/11 Due: 11/30/12

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Phase: N/A Priority: Normal
NCT ID: NCT04614571 Org: User:
Start: 11/02/20 End: 05/30/24 Due: 05/30/25

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT02520245 Org: User:
Start: 08/31/15 End: 11/30/23 Due: 11/30/24

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Phase: N/A Priority: Normal
NCT ID: NCT04417894 Org: User:
Start: 04/14/21 End: 11/23/22 Due: 11/23/23

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT02277743 Org: User:
Start: 10/31/14 End: 02/29/16 Due: 02/28/17

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

Phase: N/A Priority: Normal
NCT ID: NCT04666441 Org: User:
Start: 12/15/20 End: 09/21/21 Due: 09/21/22

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03530514 Org: User:
Start: 04/24/18 End: 01/27/20 Due: 01/27/21

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05546957 Org: User:
Start: 01/05/23 End: 04/06/23 Due: 04/06/24

Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02828397 Org: User:
Start: 04/30/16 End: 09/30/16 Due: 09/30/17

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase: N/A Priority: Normal
NCT ID: NCT06028594 Org: User:
Start: - End: - Due: -

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01727869 Org: User:
Start: 10/31/12 End: 01/31/15 Due: 01/31/16

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03430063 Org: User:
Start: 05/29/18 End: 10/27/21 Due: 10/27/22

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04695977 Org: User:
Start: 02/24/21 End: 07/22/24 Due: 07/22/25

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Phase: N/A Priority: Normal
NCT ID: NCT03949673 Org: User:
Start: 04/08/19 End: 08/25/20 Due: 08/25/21

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06190951 Org: User:
Start: 09/18/24 End: 04/23/31 Due: 04/23/32

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02516618 Org: User:
Start: 07/31/15 End: 02/29/16 Due: 02/28/17

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04940364 Org: User:
Start: 08/04/21 End: 06/22/22 Due: 06/22/23

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

Phase: N/A Priority: Normal
NCT ID: NCT03767738 Org: User:
Start: 12/19/18 End: 08/19/20 Due: 08/19/21

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT05423327 Org: User:
Start: 12/09/21 End: 10/27/22 Due: 10/27/23

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00082823 Org: User:
Start: 01/31/04 End: - Due: -

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Phase: N/A Priority: Normal
NCT ID: NCT04515524 Org: User:
Start: 02/05/21 End: 11/05/26 Due: 11/05/27

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Phase: N/A Priority: Normal
NCT ID: NCT06970405 Org: User:
Start: 05/29/25 End: 06/08/26 Due: 06/08/27

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01011959 Org: User:
Start: 12/31/08 End: 08/31/09 Due: 08/31/10